Phase II trial on Programmed death-One inhibitor plus RadioThERapy in patients with Metastatic Mucosal Melanoma
- Conditions
- Metastatic Mucosal Melanoma
- Registration Number
- JPRN-UMIN000030533
- Lead Sponsor
- Kyoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 20
Not provided
1) Synchronous or metachronous (within 5 years) malignancies except for carcinoma in situ or mucosal tumors curatively treated with local therapy. 2) The current radiation field do not overlap the previous radiation field. 3) Active infection requiring systemic therapy. 4) Patients with immune suppression. 5) Patients with central nerve system metastases. 6) Patients with complications of autoimmune disease, histories of chronic and recurrent autoimmune disease or other diseases which require systemic steroid therapy or immune suppressor. 7) Patients received live vaccines. 8) Pregnancy, possible pregnancy or breastfeeding. 9) Psychiatric disease. 10) Patients requiring systemic steroid medication. 11) Severe pulmonary fibrosis or emphysema. 12) Patients whom principle/sub-investigator judged ineligible to participate in this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method